ALPHAMAB ONCOLOGY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.75 HKD | +0.21% |
|
+13.91% | -28.46% |
ETFs positioned on Alphamab Oncology
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.21% | 4 M€ | -27.92% | ||
| 0.06% | 2 M€ | -14.14% | ||
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | -0.21% | - | |
| 0.00% | 34 M€ | +1.85% | - |
Alphamab Oncology is an investment holding company primarily engaged in the biopharmaceutical business. The Company is a full-industry chain enterprise specializing in research, development, manufacture, and commercialization of innovative tumor immunobiology macromolecular targeted drugs. The Company has bio-innovation drug development technology platform, including protein engineering platform, multi-functional antibody development platform and antibody screening platform. The Company operates its businesses in both domestic and overseas markets.
Calendar
2024-06-11
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
4.396
CNY
Average target price
4.211
CNY
Spread / Average Target
-4.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.46% | 586M | |
| +1.22% | 42.19B | |
| +44.30% | 40.15B | |
| -6.20% | 28.31B | |
| +7.10% | 24.63B | |
| -21.81% | 18.2B | |
| +29.18% | 12.01B | |
| -1.19% | 11.76B | |
| +15.98% | 10.4B | |
| -4.08% | 9.94B |
- Stock Market
- Equities
- 9966 Stock
- Funds and ETFs Alphamab Oncology
